Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 mg Once Daily With Food Versus Dolutegravir 50 mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 08 Aug 2019 Status changed from not yet recruiting to recruiting.
- 08 Aug 2019 Planned End Date changed from 31 Mar 2021 to 30 Jun 2021.
- 08 Aug 2019 Planned primary completion date changed from 31 Mar 2021 to 30 Jun 2021.